Media Articles Related to Avonex (Interferon Beta-1A)
Multiple sclerosis: Results from ZINBRYTA Phase 3 DECIDE study highlighting efficacy compared to Interferon Beta-1a published
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.10.09]
Full results from the Phase 3 DECIDE study published this week in the New England Journal of Medicine (NEJM), as well as new post-hoc analyses of Phase 3 clinical data presented at an international...
Published Studies Related to Avonex (Interferon Beta-1A)
Cognitive dysfunction in patients with multiple sclerosis treated with different
types of interferon beta: a randomized clinical trial. 
function in MS... CONCLUSIONS: Different types of DMTs may improve some aspects of cognitive
Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular
Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of
measurements in two different laboratories. 
The appearance of neutralizing antibodies (NAbs) has significant clinical and
regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing
remitting MS were enrolled in a 24month study period... As similar
results were obtained from CinnoVex or Avonex in our study, we suggest that both
medications will have a similar immunogenetic profile.
Comparing efficacy and side effects of a weekly intramuscular
biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting
multiple sclerosis: a double blind randomized clinical trial. 
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year
follow-up of the ASA cohort. 
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term
Interferon beta for secondary progressive multiple sclerosis. 
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients
Clinical Trials Related to Avonex (Interferon Beta-1A)
Immunogenicity and Safety Study of Serum-Free Avonex [Completed]
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given
to interferon beta naive patients with relapsing/remitting multiple sclerosis.
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers [Completed]
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe [Completed]
Determine patient satisfaction with the single-use autoinjector for the delivery of
pre-filled Avonex syringe.
Evaluate the Safe and Effective Use of the Avonex´┐Ż Single-Use Autoinjector in Multiple Sclerosis Subjects [Completed]
The primary objective of the study was to evaluate the safe and effective use of the
single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex« (interferon
beta-1a) in participants with multiple sclerosis (MS).
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) [Completed]
The study is designed to determine the effect of weekly intramuscular (IM) administration of
30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and
T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with
clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).
Reports of Suspected Avonex (Interferon Beta-1A) Side Effects
Influenza Like Illness (821),
Multiple Sclerosis Relapse (734),
Gait Disturbance (517),
Memory Impairment (355),
Injection Site Pain (335),
Injection Site Haemorrhage (316), more >>